How a ‘one and done’ gene-editing treatment could lower cholesterol – The Washington Post
- How a ‘one and done’ gene-editing treatment could lower cholesterol The Washington Post
- CRISPR Therapeutics (Nasdaq: CRSP) announces 73% ANGPTL3 drop in Phase 1 CTX310 trial Stock Titan
- CRISPR gene therapy slashes ‘bad’ cholesterol, triglycerides by half in small study MarketScreener
- Scientists have edited a gene that may reduce high cholesterol permanently CNN
- First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides www.heart.org